[go: up one dir, main page]

PE20151072A1 - Derivados de (cicloalquilen) bis (1, 3, 4-tiadiazol) como inhibidores de glutaminasa - Google Patents

Derivados de (cicloalquilen) bis (1, 3, 4-tiadiazol) como inhibidores de glutaminasa

Info

Publication number
PE20151072A1
PE20151072A1 PE2015000674A PE2015000674A PE20151072A1 PE 20151072 A1 PE20151072 A1 PE 20151072A1 PE 2015000674 A PE2015000674 A PE 2015000674A PE 2015000674 A PE2015000674 A PE 2015000674A PE 20151072 A1 PE20151072 A1 PE 20151072A1
Authority
PE
Peru
Prior art keywords
cycloalkylene
compounds
tiadiazol
bis
derivatives
Prior art date
Application number
PE2015000674A
Other languages
English (en)
Inventor
Rene M Lemieux
Janeta Popovici-Muller
Francesco G Salituro
Jeffrey O Saunders
Jeremy M Travins
Yongsheng Chen
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of PE20151072A1 publication Critical patent/PE20151072A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

En la presente se describen compuestos y composiciones que comprenden compuestos que inhiben la glutaminasa. En la presente tambien se describen metodos para emplear los compuestos que inhiben la glutaminasa en el tratamiento del cancer. Los compuestos de la invencion son de formula (I), donde X es cicloalquileno C3-C7; W, Y y Z son S, etc; R1, R2 son NH2, etc; R3 es H, etc, R6 es H, etc, m y n son 0, 1 o 2, o y p son 1, 2 o 3. Los compuestos preferidos son (S)-N-(5-((1S,3S)-3-(5-(2-(6-(3,3-difluoroazetidin-1-il)piridin-2-il)acetamido)-1,3,4-tiadiazol-2-il) ciclohexil)-1, 3, 4-tiadiazol-2-il) -2-hidroxi-2-fenilacetamida; 2-(6-(3,3-difluoroazetidin-1-il) piridin-2-il)-N-(5-((1S, 3S)-3-(5-(2-(3-(trifluorometoxi) fenil)acetamido)-1, 3, 4-tiadiazol-2-il) ciclohexil) -1, 3, 4-tiadiazol-2-il) acetamida
PE2015000674A 2012-11-22 2013-11-21 Derivados de (cicloalquilen) bis (1, 3, 4-tiadiazol) como inhibidores de glutaminasa PE20151072A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/CN2012/085023 WO2014079011A1 (en) 2012-11-22 2012-11-22 Heterocyclic compounds for inhibiting glutaminase and their methods of use
PCT/CN2013/000294 WO2014079136A1 (en) 2012-11-22 2013-03-15 Compounds, pharmaceutical compositions and uses as glutaminase inhibitors for treating cancers thereof
PCT/CN2013/001428 WO2014079150A1 (en) 2012-11-22 2013-11-21 Compounds and their methods of use

Publications (1)

Publication Number Publication Date
PE20151072A1 true PE20151072A1 (es) 2015-08-26

Family

ID=50775393

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015000674A PE20151072A1 (es) 2012-11-22 2013-11-21 Derivados de (cicloalquilen) bis (1, 3, 4-tiadiazol) como inhibidores de glutaminasa

Country Status (36)

Country Link
US (2) US10087172B2 (es)
EP (2) EP2922850B1 (es)
JP (2) JP6333277B2 (es)
KR (1) KR20150085079A (es)
CN (2) CN108727307A (es)
AR (1) AR093598A1 (es)
AU (2) AU2013347771B2 (es)
BR (1) BR112015011830A2 (es)
CA (1) CA2893510C (es)
CL (1) CL2015001392A1 (es)
CR (1) CR20150316A (es)
CY (1) CY1120581T1 (es)
DK (1) DK2922850T3 (es)
EA (2) EA201890754A1 (es)
EC (1) ECSP15026557A (es)
ES (1) ES2690390T3 (es)
HR (1) HRP20181628T1 (es)
HU (1) HUE040111T2 (es)
IL (1) IL238958B (es)
LT (1) LT2922850T (es)
MX (1) MX367389B (es)
MY (1) MY177344A (es)
NZ (1) NZ708382A (es)
PE (1) PE20151072A1 (es)
PH (2) PH12015501150B1 (es)
PL (1) PL2922850T3 (es)
PT (1) PT2922850T (es)
RS (1) RS57859B1 (es)
SA (1) SA515360469B1 (es)
SG (2) SG10201609940RA (es)
SI (1) SI2922850T1 (es)
SM (1) SMT201800504T1 (es)
TR (1) TR201812360T4 (es)
TW (2) TWI629268B (es)
UA (1) UA117360C2 (es)
WO (3) WO2014079011A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
US10793535B2 (en) 2012-11-16 2020-10-06 Calithera Biosciences, Inc. Heterocyclic glutaminase inhibitors
AU2013347933C1 (en) 2012-11-21 2018-10-04 Agios Pharmaceuticals, Inc. Glutaminase inhibitors and methods of use
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
WO2014089048A1 (en) * 2012-12-03 2014-06-12 Calithera Biosciences, Inc. Treatment of cancer with heterocyclic inhibitors of glutaminase
WO2014110574A1 (en) 2013-01-14 2014-07-17 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
PT2945939T (pt) 2013-01-15 2020-06-08 Incyte Holdings Corp Compostos tiazole e piridina carboxamidas úteis como inibidores das quinases pim
US9556197B2 (en) 2013-08-23 2017-01-31 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
CN105960405B (zh) 2014-01-06 2021-02-19 理森制药股份公司 谷氨酰胺酶抑制剂
MX2016012244A (es) 2014-03-21 2017-05-08 Agios Pharmaceuticals Inc Compuestos y sus metodos de uso.
GEAP201814314A (en) * 2014-04-30 2018-03-26 Pfizer Cycloalkyl-linked diheterocycle derivatives
GB201409624D0 (en) 2014-05-30 2014-07-16 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
JP6619758B2 (ja) 2014-07-03 2019-12-11 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 疾患を処置するためのｇｌｓ１阻害薬
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016014890A1 (en) * 2014-07-24 2016-01-28 Calithera Biosciences, Inc. Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase
CA2957225A1 (en) 2014-08-07 2016-02-11 Calithera Biosciences, Inc. Crystal forms of glutaminase inhibitors
WO2016054388A1 (en) 2014-10-03 2016-04-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Glutaminase inhibitors
US10441587B2 (en) 2015-04-06 2019-10-15 Calithera Biosciences, Inc. Treatment of lung cancer with inhibitors of glutaminase
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
EP3316887B1 (en) 2015-06-30 2020-04-08 Board of Regents, The University of Texas System Gls1 inhibitors for treating disease
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
EP3359150A4 (en) 2015-10-05 2019-11-06 Calithera Biosciences, Inc. COMBINATION THERAPY WITH GLUTAMINASE INHIBITORS AND IMMUNO-ONCOLOGICAL AGENTS
US10040789B2 (en) * 2015-11-30 2018-08-07 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
CN106890184B (zh) * 2015-12-18 2019-06-25 诺言医药科技(上海)有限公司 抗肿瘤的谷氨酰胺酶抑制剂和肿瘤血管生成抑制剂药物组合物及其应用
AU2016378746B2 (en) 2015-12-22 2021-05-20 Board Of Regents, The University Of Texas System Salt forms and polymorphs of (R)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl) acetamido) pyridazin-3-yl)-2-fluorobutyl)-N-methyl-1H-1,2,3-triazole-4-carboxamide
JP2019526560A (ja) 2016-08-25 2019-09-19 キャリセラ バイオサイエンシーズ， インコーポレイテッド グルタミナーゼ阻害剤との併用療法
JP2019524852A (ja) 2016-08-25 2019-09-05 キャリセラ バイオサイエンシーズ， インコーポレイテッド グルタミナーゼ阻害剤を用いる併用療法
RU2020112558A (ru) 2017-10-18 2021-11-18 Боард Оф Регентс, Зе Юниверсити Оф Тексас Систем Терапия на основе ингибитора глутаминазы
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
CA3102279A1 (en) 2018-06-01 2019-12-05 Cornell University Combination therapy for pi3k-associated disease or disorder
US20210403479A1 (en) 2018-11-08 2021-12-30 Merck Sharp & Dohme Corp. Inhibitors of histone deacetylase useful for the treatment or prevention of hiv infection
WO2020191356A1 (en) * 2019-03-21 2020-09-24 Goncalves Marcus Anti-fructose therapy for colorectal and small intestine cancers
CN110746416A (zh) * 2019-09-05 2020-02-04 中国药科大学 含有三氮唑结构的谷氨酰胺酶gls1抑制剂或其可药用的盐、其制备方法及用途
CN112898200A (zh) * 2021-01-20 2021-06-04 都创(上海)医药科技股份有限公司 5-溴-6-甲氧基吡啶-2-羧酸酯的合成方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2037257A1 (en) 1970-07-28 1972-02-03 Farbwerke Hoechst AG, vorm. Meister Lucius & Brüning, 6000 Frankfurt Poly-(5-amino-1,3,4-thiadiazol-2-yl) derivs prepn - intermediates for drug and polymer prodn
US4070400A (en) 1975-10-16 1978-01-24 Merck & Co., Inc. Diphenyl polyamides having a cyclohexylene moiety
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
CA1291031C (en) 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Method for the detection of specific binding agents and their correspondingbindable substances
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
SU1761672A1 (ru) * 1990-05-22 1992-09-15 Белгородский технологический институт строительных материалов им.И.А.Гришманова Способ получени тонкодисперсного мела
JPH08508270A (ja) 1993-03-29 1996-09-03 ビーエーエスエフ アクチエンゲゼルシャフト マルチ・ドラッグ耐性のモジュレーターとしての１−アミノ−３−フェノキシ−プロパン誘導体
US5895748A (en) 1996-11-27 1999-04-20 Johnson; Keith R. Panel of antibodies for detecting cadherins and catenins in tissues and method of using the panel of antibodies
EP1087951B9 (en) * 1998-06-18 2006-09-13 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
WO2000052204A2 (en) 1999-02-22 2000-09-08 Orntoft Torben F Gene expression in bladder tumors
US20030054985A1 (en) 2000-02-22 2003-03-20 Stuart Aaronson N-cadherin modulated migration, invasion, and metastasis
US6974667B2 (en) 2000-06-14 2005-12-13 Gene Logic, Inc. Gene expression profiles in liver cancer
US6451828B1 (en) * 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
DK1388734T3 (da) 2002-08-01 2004-05-03 Mtm Lab Ag Metode til opløsningsbaseret diagnose
WO2006040569A1 (en) 2004-10-14 2006-04-20 Astex Therapeutics Limited Thiophene amide compounds for use in the treatment or prophylaxis of cancers
US20080182865A1 (en) 2005-03-11 2008-07-31 Witta Samir E Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors
CA2601157A1 (en) 2005-03-16 2006-09-28 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
WO2008048967A1 (en) 2006-10-16 2008-04-24 University Of Rochester Tripodal cyclohexane derivatives and their use as carbohydrate receptors
WO2009067429A1 (en) 2007-11-19 2009-05-28 Genentech, Inc. Compositions and methods for inhibiting tumor progression
WO2009111067A2 (en) 2008-03-07 2009-09-11 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal -like tumor cells or their formation
US20120190565A1 (en) 2009-02-20 2012-07-26 Pangea Biosciences, Inc. Method Of Diagnosis Or Prognosis Of A Neoplasm Comprising Determining The Level Of Expression Of A Protein In Stromal Cells Adjacent To The Neoplasm
WO2010111504A2 (en) 2009-03-25 2010-09-30 Cornell University Inhibition of glutaminase c
WO2010120966A1 (en) 2009-04-17 2010-10-21 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
US20130109643A1 (en) * 2010-05-10 2013-05-02 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
JP5944385B2 (ja) 2010-06-23 2016-07-05 ユニバーシティ オブ ルーイビル リサーチ ファウンデーション，インコーポレーテッド 癌を検出するための方法
WO2012006506A1 (en) * 2010-07-09 2012-01-12 Massachusetts Institute Of Technology Metabolic gene, enzyme, and flux targets for cancer therapy
UY33930A (es) 2011-03-04 2012-10-31 Novartis Ag Inhibidores novedosos de quinasas
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CA2856386C (en) * 2011-11-21 2022-05-31 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
CA2867456A1 (en) 2012-03-15 2013-09-19 The Research Foundation For The State University Of New York Combination therapies including inhibitors of the extracellular domain of e-cadherin
AU2013347933C1 (en) 2012-11-21 2018-10-04 Agios Pharmaceuticals, Inc. Glutaminase inhibitors and methods of use
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
US20160008380A1 (en) 2013-03-06 2016-01-14 The Johns Hopkins University Targeting glutamine metabolism in brain tumors
CN105960405B (zh) 2014-01-06 2021-02-19 理森制药股份公司 谷氨酰胺酶抑制剂
MX2016012244A (es) 2014-03-21 2017-05-08 Agios Pharmaceuticals Inc Compuestos y sus metodos de uso.

Also Published As

Publication number Publication date
HUE040111T2 (hu) 2019-02-28
EA030646B1 (ru) 2018-09-28
CN108727307A (zh) 2018-11-02
AU2013347771B2 (en) 2018-02-01
US10087172B2 (en) 2018-10-02
WO2014079150A1 (en) 2014-05-30
EP2922850A4 (en) 2016-05-18
CN104936954B (zh) 2018-08-14
IL238958A0 (en) 2015-07-30
JP2016500082A (ja) 2016-01-07
TW201906825A (zh) 2019-02-16
WO2014079011A1 (en) 2014-05-30
AU2013347771A1 (en) 2015-06-11
EP2922850A1 (en) 2015-09-30
AR093598A1 (es) 2015-06-10
CR20150316A (es) 2015-08-28
CL2015001392A1 (es) 2016-04-22
ES2690390T3 (es) 2018-11-20
ECSP15026557A (es) 2016-01-29
WO2014079136A1 (en) 2014-05-30
TWI629268B (zh) 2018-07-11
EP3456719A1 (en) 2019-03-20
HK1214593A1 (en) 2016-07-29
DK2922850T3 (en) 2018-10-08
AU2018202954A1 (en) 2018-05-17
EA201590987A1 (ru) 2015-12-30
PL2922850T3 (pl) 2018-12-31
RS57859B1 (sr) 2018-12-31
JP6333277B2 (ja) 2018-05-30
LT2922850T (lt) 2018-09-10
US20150291576A1 (en) 2015-10-15
TR201812360T4 (tr) 2018-09-21
MX367389B (es) 2019-08-19
SMT201800504T1 (it) 2018-11-09
PH12017502141A1 (en) 2019-02-27
SG10201609940RA (en) 2016-12-29
KR20150085079A (ko) 2015-07-22
MX2015006493A (es) 2015-08-05
EP2922850B1 (en) 2018-07-18
PT2922850T (pt) 2018-10-15
CA2893510C (en) 2021-01-19
MY177344A (en) 2020-09-13
US10689375B2 (en) 2020-06-23
UA117360C2 (uk) 2018-07-25
CY1120581T1 (el) 2019-07-10
CN104936954A (zh) 2015-09-23
US20190084976A1 (en) 2019-03-21
NZ708382A (en) 2020-04-24
SA515360469B1 (ar) 2017-07-11
JP2018150316A (ja) 2018-09-27
HRP20181628T1 (hr) 2018-12-14
IL238958B (en) 2019-09-26
SG11201504049VA (en) 2015-07-30
TW201427963A (zh) 2014-07-16
PH12015501150A1 (en) 2015-08-17
PH12015501150B1 (en) 2018-05-04
CA2893510A1 (en) 2014-05-30
BR112015011830A2 (pt) 2017-07-11
EA201890754A1 (ru) 2018-08-31
SI2922850T1 (sl) 2018-10-30

Similar Documents

Publication Publication Date Title
PE20151072A1 (es) Derivados de (cicloalquilen) bis (1, 3, 4-tiadiazol) como inhibidores de glutaminasa
PH12019500932A1 (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
MX2022002581A (es) Compuestos de benzimidazol como inhibidores de c-kit.
MX2022002579A (es) Compuestos de aminotiazol como inhibidores de c- kit.
CY1120834T1 (el) Δικυκλικες αζωτουχες ενωσεις ως αγωνιστες μουσκαρινικων υποδοχεων μ1
PE20141404A1 (es) Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas
NZ709609A (en) Benzylamine derivatives
PH12015502549B1 (en) Heterocyclic derivatives
CU20170087A7 (es) Formas cristalinas de 5-(4-ciclopropil-1 h-imidazol-1-il)-n-(6-(4-isopropil-4h-1 , 2, 4- triazol-3-il)piridin-2-il)-2-fluoro-4-metilbenzamida
PE20140626A1 (es) Compuestos de bis(fluoroalquil)-1,4-benzodiazepinona
PE20160524A1 (es) Compuestos terapeuticamente activos y sus metodos de uso
PE20170695A1 (es) Compuestos de indol carboxamida utiles como inhibidores de cinasas
MX368066B (es) Derivados de quinazolin-4-ona sustituida.
PE20170004A1 (es) Inhibidores de biaril cinasa
UY35242A (es) Inhibidores de fosfatidilinositol 3-quinasa
PE20161073A1 (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
PH12018500987A1 (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
UY34451A (es) Derivados de uracilo como inhibidores de la quinasa axl y c-met
MX2018015657A (es) Compuestos heterociclico como antibacterianos.
CY1120355T1 (el) Αναστολεις toy iap
SG10201806965XA (en) 3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer
EA202091120A3 (ru) Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы
PE20170148A1 (es) Compuestos de 1,3, 4-tiadiazol y uso de los mismos para el tratamiento del cancer
PE20151748A1 (es) Inhibidores de bace1
NZ627631A (en) Benzoheterocyclic compounds and use thereof